EXPRES2ION BIOTECH HOLDING AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.418 SEK | -1.53% |
|
-3.54% | -32.80% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 300.9 | 1,145 | 621.6 | 74.02 | 74.02 | - |
| Enterprise Value (EV) 1 | 300.9 | 1,008 | 512.4 | 51.14 | 70.4 | 113.4 |
| P/E ratio | -5.92 x | -24.5 x | -4.89 x | -1.01 x | -1.48 x | -1.85 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 83.4 x | 101 x | 12.3 x | 8.71 x | 8.71 x |
| EV / Revenue | - | 73.4 x | 83.3 x | 5.81 x | 8.28 x | 13.3 x |
| EV / EBITDA | - | -21.6 x | -4.05 x | -0.49 x | -1.41 x | -2.84 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | 8.16 x | 5.61 x | 1.78 x | 19.8 x | -2.04 x |
| Nbr of stocks (in thousands) | 27,608 | 31,153 | 37,607 | 51,405 | 51,405 | - |
| Reference price 2 | 10.90 | 36.76 | 16.53 | 1.440 | 1.440 | 1.440 |
| Announcement Date | 21-02-25 | 22-02-24 | 23-02-09 | 24-02-08 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 13.73 | 6.15 | 8.799 | 8.5 | 8.5 |
| EBITDA 1 | - | -46.59 | -126.4 | -104.4 | -50 | -40 |
| EBIT 1 | - | -48.4 | -127.6 | -106 | -50 | -40 |
| Operating Margin | - | -352.48% | -2,074.89% | -1,204.28% | -588.24% | -470.59% |
| Earnings before Tax (EBT) 1 | - | -47.52 | -126.6 | -104.6 | -50.04 | -40.04 |
| Net income 1 | -31.99 | -43.92 | -118.6 | -95.99 | -50.04 | -40.04 |
| Net margin | - | -319.92% | -1,928.54% | -1,090.91% | -588.7% | -471.01% |
| EPS 2 | -1.840 | -1.500 | -3.380 | -2.080 | -0.9734 | -0.7788 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 21-02-25 | 22-02-24 | 23-02-09 | 24-02-08 | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 39.4 |
| Net Cash position 1 | - | 137 | 109 | 57.3 | 3.63 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.9852 x |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 4.510 | 2.940 | 1.190 | 0.0700 | -0.7100 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 21-02-25 | 22-02-24 | 23-02-09 | 24-02-08 | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.44
SEK
Average target price
9
SEK
Spread / Average Target
+525.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.80% | 6.93M | |
| +0.10% | 91.42B | |
| +2.76% | 41.08B | |
| -9.06% | 34.26B | |
| +53.99% | 25.27B | |
| -16.61% | 15.27B | |
| -9.14% | 12.81B | |
| -12.11% | 11.6B | |
| -43.61% | 11.42B | |
| +3.67% | 9.16B |
- Stock Market
- Equities
- EXPRS2 Stock
- Financials ExpreS2ion Biotech Holding AB
